Financial Performance & Outlook - The company reported revenue of RMB 446 million, a 48% year-over-year increase, primarily driven by NEFECON® and XERAVA®[10, 12] - Gross margin was 76.4%, excluding amortization of intangible assets, reflecting NRDL price reduction of NEFECON® in mainland China and product cost optimization[10, 13] - Non-IFRS net loss decreased by 31% year-over-year to RMB 147 million[10] - The company expects full-year revenue to be between RMB 1.6 billion and RMB 1.8 billion, with NEFECON® revenue projected at RMB 1.2 billion to RMB 1.4 billion[10] - The company anticipates achieving operational profitability in the second half of 2025[9, 11] Key Products & Commercialization - NEFECON® revenue reached RMB 825 million from January to August 2025, with full NRDL coverage achieved in target provinces[8, 20] - NEFECON® is projected to generate RMB 1.2 billion to RMB 1.4 billion in revenue for the full year 2025 and RMB 2.4 billion to RMB 2.6 billion in 2026[10, 25] - XERAVA® generated RMB 143 million in revenue in the first half of 2025, a 6% year-over-year increase, with in-market sales up by 37%[32] - VELSIPITY® demonstrated a 51.9% mucosal healing rate with one year of treatment and is estimated to reach peak sales exceeding RMB 5 billion[49, 52] R&D Pipeline & Investments - EVER001 (Civorebrutinib) showed rapid and deep reductions in both Anti-PLA2R and 24h Proteinuria with an excellent safety profile[67] - The company completed a share placement on August 1, 2025, with net proceeds of HKD 1.6 billion[8, 10] - The company increased its strategic investment in I-MAB, becoming its single largest shareholder with 16.1% ownership[8, 116]